

EFFECTIVE DATE: 03|01|2007

POLICY LAST UPDATED: 12|01|2014

OVERVIEW

Gastric electrical stimulation is performed using an implantable device designed to treat chronic drug-refractory nausea and vomiting secondary to gastroparesis of diabetic, idiopathic, or post-surgical etiology. Gastric electrical stimulation has also been investigated as a treatment of obesity. The device may be referred to as a gastric pacemaker. This policy is intended to document the insertion or implantation of the device as not medically necessary.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare and Commercial Products

Implantation of a gastric electrical stimulation device for any indication is considered **not medically necessary** because there is insufficient medical literature to support the efficacy of this treatment.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for limitations of benefits/coverage when services are not medically necessary.

BACKGROUND

Gastroparesis is a chronic disorder of gastric motility characterized by delayed emptying of a solid meal. Symptoms include bloating, distension, nausea, and vomiting. When severe and chronic, gastroparesis can be associated with dehydration, poor nutritional status, and poor glycemic control in diabetic patients. While most commonly associated with diabetes, gastroparesis is also found in chronic pseudo-obstruction, connective tissue disorders, Parkinson's disease, and psychological pathologic conditions. Some cases may not be associated with an identifiable cause, and are referred to as idiopathic gastroparesis. Treatment of gastroparesis includes prokinetic agents, such as metoclopramide, and antiemetic agents, such as metoclopramide, granisetron, or ondansetron. Severe cases may require enteral or total parenteral nutrition.

Gastric electrical stimulation, also referred to as gastric pacing, using an implantable device, has been investigated primarily as a treatment for gastroparesis. Currently available devices consist of a pulse generator, which can be programmed to provide electrical stimulation at different frequencies, connected to intramuscular stomach leads that are implanted during laparoscopy or open laparotomy.

Gastric electrical stimulation has also been investigated as a treatment of obesity as a technique to increase a feeling of satiety with subsequent reduced food intake and weight loss. The exact mechanisms resulting in changes in eating behavior are uncertain but may be related to neuro-hormonal modulation and/or stomach muscle stimulation. There are no gastric electrical stimulation devices approved by the U.S. Food and Drug Administration (FDA) for the treatment of obesity. The Transcend® Implantable Gastric Stimulation device,

manufactured by Transneuronix Corporation and acquired by Medtronic in 2005, is currently available in Europe for treatment of obesity. Medtronic announced in December 2005 that the preliminary results of the Screened Health Assessment and Pacer Evaluation, or SHAPE trial, which was initiated by Transneuronix using the Transcend device, “did not meet the efficacy endpoint of a difference in mean excess weight loss at one year.”

Currently, only one gastric electrical stimulator has received approval from the FDA, the Gastric Electrical Stimulator (GES) system (now called Enterra™ Therapy System), manufactured by Medtronic. The GES system consists of 4 components: the implanted pulse generator, 2 unipolar intramuscular stomach leads, the stimulator programmer, and the memory cartridge. With the exception of the intramuscular leads, all other components have been used in other implantable neurologic stimulators, such as spinal cord or sacral nerve stimulation. The intramuscular stomach leads are implanted either laparoscopically or during a laparotomy and are connected to the pulse generator, which is implanted in a subcutaneous pocket. The programmer sets the stimulation parameters, which are typically set at an “on” time of 0.1 sec alternating with an “off” time of 5.0 sec.

The evidence on the efficacy of gastric electrical stimulation to treat gastroparesis is inadequate to permit scientific conclusions about its efficacy. Therefore, gastric electrical stimulation for the treatment of gastroparesis of diabetic, idiopathic, or post-surgical etiologies is considered not medically necessary. Additionally, case series publications are limited and insufficient to draw conclusions on health outcomes of gastric electrical stimulation for the treatment of obesity. Therefore, gastric electrical stimulation as treatment for obesity is considered not medically necessary.

CODING

BlueCHiP for Medicare and Commercial Products

The following code is not medically necessary when used for gastric electrical stimulation and filed with the diagnosis codes listed below:

64590

ICD-9

249.60	250.60	250.62	278.00	536.3
249.61	250.61	250.63	278.01	997.49

ICD-10

E08.40	E09.43	E11.40	E66.01	E66.3
E08.43	E10.40	E11.43	E66.09	E66.8
E08.65	E10.43	E11.65	E66.1	E66.9
E09.40	E10.65	E13.43	E66.2	K91.89

The following codes are **not medically necessary**:

43647

43881

95980

95981

95982

RELATED POLICIES

Preauthorization via Web-Based Tool for Procedures

PUBLISHED

Provider Update, February 2016
Provider Update, July 2014
Provider Update, August 2013
Provider Update, July 2012
Provider Update, August 2010
Provider Update, August 2011
Provider Update, September 2009

REFERENCES

1. Chu H, Lin Z, Zhong L et al. Treatment of high-frequency gastric electrical stimulation for gastroparesis. *J Gastroenterol Hepatol* 2012; 27(6):1017-26.
2. Abell T, McCallum R, Hocking M et al. Gastric electrical stimulation for medically refractory gastroparesis. *Gastroenterology* 2003; 125(2):421-8.
3. McCallum RW, Snape W, Brody F et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. *Clin Gastroenterol Hepatol* 2010; 8(11):947-54; quiz e116.
4. FDA Summary of Safety and Probable Benefit. Available online at: http://www.accessdata.fda.gov/cdrh_docs/pdf/H990014b.pdf. Last accessed July 2013.
5. Anand C, Al-Juburi A, FAMILONI B et al. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers. *Digestion* 2007; 75(2-3):83-9.
6. Abell T, Lou J, Tabbaa M et al. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. *JPEN J Parenter Enteral Nutr* 2003; 27(4):277-81.
7. Forster J, Sarosiek I, Lin Z et al. Further experience with gastric stimulation to treat drug refractory gastroparesis. *Am J Surg* 2003; 186(6):690-5.
8. van der Voort IR, Becker JC, Dietl KH et al. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. *Exp Clin Endocrinol Diabetes* 2005; 113(1):38-42.
9. Lahr CJ, Griffith J, Subramony C et al. Gastric electrical stimulation for abdominal pain in patients with symptoms of gastroparesis. *Am Surg* 2013; 79(5):457-64.
10. Abell TL, Johnson WD, Kedar A et al. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. *Gastrointest Endosc* 2011; 74(3):496-503 e3.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

